Tag: clinical trial
-
Experimental Gene Therapy Restores Immune Function in Children with ADA-SCID: A Breakthrough in Immunodeficiency Treatment
Overview: A new path for ADA-SCID treatment Researchers from UCLA, University College London, and Great Ormond Street Hospital have reported a remarkable milestone in the fight against ADA-SCID, a rare and often fatal genetic immune disorder. In a long-term study published in the New England Journal of Medicine, an experimental gene therapy restored and sustained…
-
Immunotherapy for HIV: Early PD-1 Treatment Shows Potential for Drug-Free Viral Control
Overview: A new immunotherapy approach in HIV Researchers report promising safety data from the first-in-human trial of an anti-PD-1 antibody, budigalimab, in people living with HIV. The study, published in Nature Medicine, explored whether a cancer immunotherapy could be used at low doses to augment the immune system’s ability to control HIV without daily antiretroviral…
-
Pectin Prebiotics Show Promise for Food Allergy Treatment
Gut Dysbiosis and Food Allergy: A New Frontier Food allergy (FA) is a growing health concern worldwide, with the Mediterranean region reporting a notable role for plant-based foods and lipid transfer proteins (LTPs) such as Pru p 3 from peaches. Symptoms can range from mild oral allergy syndrome to life-threatening anaphylaxis, underscoring the need for…
-
Immunotherapy for HIV: Early Trials of Anti-PD1 Drug Budigalimab Suggest Drug-Free Viral Control
Immunotherapy Offers a New Avenue in HIV Management Researchers are cautiously optimistic about a novel immunotherapy approach that could one day reduce or even eliminate the need for daily HIV medications. In a first-in-human Phase 1b trial, budigalimab, a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) pathway, was tested in people…
-
Azelastine Nasal Spray Shows Promise in Reducing COVID-19 and Rhinovirus Infections
Overview: A nasal spray with antiviral potential A recent Phase 2 randomized clinical trial explored whether azelastine nasal spray could reduce infections with SARS-CoV-2, the virus behind COVID-19, and rhinovirus, a common cause of the cold. Conducted at a single center and funded by the spray’s manufacturer, the study enrolled 450 adults and compared 0.1%…
-
Avelumab and Radiation Show Promise for Leptomeningeal Disease
Promising early results for avelumab plus radiation in leptomeningeal disease In a small but encouraging phase 1B study, researchers at Moffitt Cancer Center report that the immunotherapy drug avelumab, when given with whole-brain radiotherapy, may offer a new, potentially safer and more effective option for leptomeningeal disease (LMD). The findings, published in Neuro-Oncology, come from…
-
Avelumab with Radiation for Leptomeningeal Disease: Momentum
Introduction Leptomeningeal disease, in which cancer cells invade the membranes surrounding the brain and spinal cord, remains one of oncology’s most daunting challenges. Patients face rapid neurological decline, and survival is often measured in weeks to months. In a phase 1B study from Moffitt Cancer Center, researchers explored whether combining the immunotherapy drug avelumab with…
-
Pembrolizumab doubles survival in head and neck cancer: KEYNOTE-689 findings
New hope for locally advanced head and neck cancer: pembrolizumab Locally advanced tumors in the head and neck region pose a formidable challenge. They are often confined to the mucosal areas, yet their proximity to the airway, esophagus, and vital vessels makes surgical removal delicate and potentially mutilating. Radiotherapy and chemotherapy add to the cure…
-
Pembrolizumab Doubles Survival in Advanced Head and Neck Cancer
The Breakthrough: A New Immunotherapy Redefines Outcomes in Locally Advanced Head and Neck Cancer Locally advanced head and neck cancer poses a formidable challenge. In many patients, the disease is detected at a stage where surgery, radiotherapy, and chemotherapy are the mainstays of treatment, yet recurrence and progression remain common. A recent advance in immunotherapy,…
-
Radiopharmaceutical Therapy Boosts Radiation to Slow Prostate Cancer
New Findings from the LUNAR Trial A landmark phase II study, known as the LUNAR trial, reports that people with recurrent prostate cancer and a limited number of metastases lived significantly longer without disease progression when a radiopharmaceutical drug was given before targeted radiation therapy, compared with high-precision radiation alone. The randomized study evaluated whether…